Your SlideShare is downloading. ×
  Recent Developments in the CNS Drug Market:Industry Analysis Report
  Recent Developments in the CNS Drug Market:Industry Analysis Report
  Recent Developments in the CNS Drug Market:Industry Analysis Report
  Recent Developments in the CNS Drug Market:Industry Analysis Report
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Recent Developments in the CNS Drug Market:Industry Analysis Report

130

Published on

Recent Developments in the CNS Drug Market:Industry Analysis Report @ http://www.researchmoz.us/recent-developments-in-the-cns-drug-market-report.html

Recent Developments in the CNS Drug Market:Industry Analysis Report @ http://www.researchmoz.us/recent-developments-in-the-cns-drug-market-report.html

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
130
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Recent Developments in the CNS Drug Market This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals across 8 key therapy areas. Despite recent technological advances, relatively few novel treatments have been launched within the CNS market over the last decade. Many of the current market leaders are beginning to face generic competition or will do within the next five years. However, the overall neuroscience market is worth approximately US$145.3 billion, and with the CNS market forming a large part of that, there is room for investment to be made. Significant unmet need remains for a number of CNS conditions and the pipeline of drug development remains strong. This new report from Espicom reviews the recent developments in drug therapy for a number of CNS disorders, providing five-year sales for the current market leaders and forecasts for these and potential therapies to 2020, where available. Key market questions answered by the report: Who are the current leading players in the CNS drugs market? What are the current treatment options for schizophrenia and bipolar disorder? What are the recent FDA approvals for depression drugs? Which new therapies will increase the value of the multiple sclerosis market? The Recent Developments in the CNS Drugs Market report is the foolproof business resource for any industry executive that needs to fully understand the current and forecasted CNS market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers. table Of Contents foreword 1 executive Summary 3 the Cns Drugs Market 4 market Overview 4 the Leading Players 6 astrazeneca 8 biogen Idec 8 eli Lilly 8 Recent Developments in the CNS Drug Market
  • 2. endo Pharmaceuticals 8 forest Laboratories 9 glaxosmithkline 9 johnson & Johnson 9 lundbeck 10 otsuka 10 pfizer 10 purdue Pharma/mundipharma/napp Pharmaceuticals 11 shire 11 teva 11 cns Market Sectors 12 pain 12 types Of Pain 12 nociceptive Pain 12 neuropathic Pain 12 psychogenic Pain 13 current Treatment Options For Pain 13 pain Drug Sales And Forecasts 15 neuropathic Pain Management 17 the World Health Organization’s Pain Ladder 18 the Pain Pipeline 18 pipeline Highlights And Recent Developments 21 levadex (dihydroergotamine) 21 moxduo Ir (morphine+oxycodone; Q8003) 22 mnk-795 (oxycodone+acetaminophen) 22 posidur (saber-bupivacaine) 23 remoxy (oxycodone) 23 zohydro Er (hydrocodone Bitartrate) 24 schizophrenia And Bipolar Disorder 25 current Treatment Options For Schizophrenia And Bipolar Disorder 25 schizophrenia Drug Sales And Forecasts 26 the Schizophrenia And Bipolar Disorder Pipeline 28 pipeline Highlights And Recent Developments 29 aripiprazole 29 cariprazine 29 fanapt/fanaptum (iloperidone) 30 depression 31 current Treatment Options For Depression 31 depression Drug Sales And Forecasts 32 Recent Developments in the CNS Drug Market
  • 3. recent Fda Approvals For Depression 34 fetzima (levominacipram) 34 brintellix (vortioxentine) 35 the Depression Pipeline 37 pipeline Highlights And Recent Developments 38 teva Scraps Nuvigil Development For Depression 38 bms Terminates Development Of Bms-820836 For Treatment-resistant Depression 38 attention Deficit Hyperactivity Disorder (adhd) 39 current Treatment Options For Adhd 39 adhd Drug Sales And Forecasts 40 the Adhd Pipeline 43 pipeline Highlights And Recent Developments 43 edivoxetine (ly2216684) 43 metadoxine Er (mg01ci) 44 eb-1020 Sr Phase Iia Pilot Study Initiated 44 highland Raises Funds To Conduct Studies With Lead Compounds 45 durect And Orient Select Lead Formulation For Oradur-adhd Programme 45 epilepsy 47 current Treatments For Epilepsy 48 epilepsy Drug Sales And Forecasts 49 the Epilepsy Pipeline 50 pipeline Highlights And Recent Developments 51 zebinix (eslicarbazepine) 51 banzel/inovelon (rufinamide) 52 brivaracetam 52 multiple Sclerosis 54 relapsing Forms Of Multiple Sclerosis 54 primary And Secondary Progressive Multiple Sclerosis 54 current Treatments For Ms 55 drug Sales And Forecasts 55 the Ms Pipeline 59 pipeline Highlights And Recent Developments 60 plegridy (peginterferon Beta-1a) 60 relonsiv (interferon Beta-1b) 60 s1p Receptor Agonists 61 arbaclofen 61 sativex For Ms Spasticity 62 neu2 Project In Support Of Diagnostic For Ms 62 alzheimer’s Disease 63 current Treatments For Ad 63 alzheimer’s Disease Drug Sales And Forecasts 63 the Ad Pipeline 65 pipeline Highlights And Recent Developments 68 Recent Developments in the CNS Drug Market
  • 4. diagnosing Ad With Pet Imaging 68 lundbeck And Otsuka Development Agreement For Lu Ae58054 68 fixed-dose Combination Of Memantine Er And Donepezil (mdx-8704/ads-8704) 69 solanezumab 70 gammagard (immunoglobulin) 70 masitinib 71 bace Inhibitors 72 nnr Modulators 73 parkinson’s Disease 74 current Treatments For Pd 74 parkinson’s Disease Drug Sales And Forecasts 75 the Pd Pipeline 76 pipeline Highlights And Recent Developments 77 dopamine Precursor + Dopa Decarboxylase Inhibitor Combinations 77 adenosine 2a Receptor Inhibition 77 safinamide 78 sources 80 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Recent Developments in the CNS Drug Market

×